Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy

NCT02381444 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 136

Last updated 2020-12-09

No results posted yet for this study

Summary

The aim of this study is to assess the effect of LCIG (levodopa-carbidopa intestinal gel) on HRQL (Health-Related Quality of Life) of participants and compare the Health-Related Quality of Life between participants continuing to levodopa-carbidopa intestinal gel treatments versus participants continuing on oral therapy for Parkinson's Disease.

Conditions

  • Parkinson's Disease (PD)

Sponsors & Collaborators

Principal Investigators

  • AbbVie Inc. · AbbVie

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-17
Primary Completion
2020-01-07
Completion
2020-01-07

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02381444 on ClinicalTrials.gov